
Kurobe, a Tampa-based biopharma firm under Point Guard Partners, specializes in treating MRSA in the eye.
Kurobe Pharmaceuticals, based in Tampa, focuses on developing treatments for methicillin-resistant staphylococcus aureus (MRSA) infections in the eye. Founded under the umbrella of Point Guard Partners LLC, Kurobe leverages a licensed product from a Japanese company to address this critical healthcare need. The company's core mission is to advance biopharmaceutical solutions for challenging infections, with a vision to improve patient outcomes through innovative therapies.
Notable figures affiliated with Kurobe include Barry Butler, who serves as President and CEO and was previously CEO of Sirion Holdings Inc. Point Guard Partners, established by former executives of Sirion Holdings, supports Kurobe's initiatives. Key achievements include the successful licensing and development of their MRSA treatment product. Kurobe's impact lies in its targeted approach to combating antibiotic-resistant infections, addressing a significant gap in ophthalmic care.
Kurobe Pharmaceuticals' most recent funding round was for $5M (USD) in June 2013.
As of Jun 4, 2013, Kurobe Pharmaceuticals has disclosed funding of $5M (USD).

Tarsus Pharmaceuticals
tarsusrx.com
MBC Pharma
mbcpharma.com

EyePoint
eyepoint.bio

BLC USA
blcusalp.com

Corbus Pharmaceuticals Holdings
corbuspharma.com

Alkeus Pharmaceuticals
alkeus.com

Zurex Pharma
zurexpharma.com

BioKier
biokier.com
MacuCLEAR

MediPrint Ophthalmics
mediprintlens.com

Ocuphire Pharma
ocuphire.com
Zocere
zocere.com

Kinnear Pharmaceuticals
kinnearpharma.com

Alphyn Biologics

Armata Pharmaceuticals
armatapharma.com

Arbutus Biopharma
arbutusbio.com
pH Pharma
ph-pharma.com

TearClear
tearclear.com

Superior Biologics
OcuCure Therapeutics
ocucure.com